Safe and Timely Antithrombotic Removal (STAR) Registry

CytoSorbents

Status: Enrolling

Conditions: Blood Loss, Postoperative; Blood Loss, Surgical; Hemorrhage, Surgical; Hemorrhage Postoperative

Treatments: Device: CytoSorb

Study type: Observational

Funder types: Industry

Identifiers

NCT05077124

O05

Details and patient eligibility

About

This registry will capture real-world clinical use patterns and associated clinical outcomes with the use of CytoSorb for the removal of antithrombotic agents.

Full description

The STAR Registry will collect patient-level clinical data on antithrombotic removal with CytoSorb. The decision to use CytoSorb in this clinical setting is based on the clinical rationale of mitigating the high risk of bleeding events that is directly linked to the presence of the antithrombotic agent. This registry is to capture real-world clinical use patterns and associated clinical outcomes with the use of CytoSorb. Data of retrospective and prospective patients will be included in the registry. Safety will be assessed by collection of (at least possibly) device-related adverse events. Data collection is done up to 30 days post-operation.

Enrollment: 1,000 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• CytoSorb utilization for antithrombotic removal
• Informed consent for prospective registry participation

Exclusion criteria

• Use of CytoSorb for purpose other than antithrombotic removal